EXACT Sciences Corporation

EXACT Sciences — Q4 2023 Earnings Presentation

16 slides from EXACT Sciences's earnings presentation, Feb 21, 2024

  1. Slide 1: Fourth-quarter 2023 earnings call

    We aim to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. Fourth-quarter 2023 earnings call February 21, 2024 EXACT SCIENCES 1

  2. Slide 2: Safe harbor and non-GAAP disclosures

    Safe harbor and non-GAAP disclosures This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are sub

  3. Slide 3: Exact Sciences is the clear leader in advanced cancer diagnostics

    Exact Sciences is the clear leader in advanced cancer diagnostics OUR TEAM OUR FLAGSHIP TESTS 2023 ACHIEVEMENTS 500 4M+ Surpassing 16M cumulative test results, including 14M with Cologuard® R&D team members tests results in 2023 1,200 Delivering record revenue of $2.5B, 24% core revenue growth perso

  4. Slide 4: Core revenue grew 18% in 4Q23

    Core revenue grew 18% in 4Q23 Core revenue Screening revenue Precision Oncology core revenue $643M $487M $544M +18% $404M +21% $157M $141M +11% 4Q22 4Q23 4Q22 4Q23 4Q22 4Q23 Please refer to our fourth-quarter 2023 earnings release at exactsciences.com for discussion of non-GAAP financial measures an

  5. Slide 5: 2024 guidance

    2024 guidance 2023 2024 ∆ at midpoint Total revenue $2.500B $2.810 - 2.850B +$330M Screening $1.865B $2.155 - 2.175B +$300M Precision Oncology $629M $655 - 675M +$36M COVID testing $6M - -$6M Adj. EBITDA $219M $325 - 350M +$119M CapEx $124M ~$150M +$26M Exact Sciences guidance provided February 21,

  6. Slide 6: Cologuard adoption continues to grow because consumers prefer it, and providers are ordering more frequently

    Cologuard adoption continues to grow because consumers prefer it, and providers are ordering more frequently orders per 0.3 provider 25 #1 0.3 ordering providers 20 0.2 preferred screening 15 test by consumers 0.2 10 0.1 0.1 5 0.0 0 2015 2016 2017 2018 2019 2020 2021 2022 2023 Source: Exact Sciences

  7. Slide 7: Building a Precision Oncology portfolio of high-quality, durable tests

    Building a Precision Oncology portfolio of high-quality, durable tests HEREDITARY EARLY-STAGE TESTING THERAPY 1.3M+ patients spared MRD LATE-STAGE unnecessary chemotherapy TESTING THERAPY (tissue) 98% (blood) U.S. oncologists have ordered Source: Exact Sciences internal data EXACT SCIENCES 7

  8. Slide 8: Progress in our colon cancer screening and molecular residual disease programs

    Progress in our colon cancer screening and molecular residual disease programs Colon cancer Expected Molecular residual screening milestones in 2024 disease Next-gen Cologuard Present colon and breast journal publication cancer validation data Next-gen Cologuard Submit for reimbursement FDA approval

  9. Slide 9: We aim to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment

    We aim to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. EXACT SCIENCES 9

  10. Slide 10: EXACT SCIENCES

    EXACT SCIENCES 10

  11. Slide 11: Condensed Consolidated Statements of Operations

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Operations (Amounts in thousands, except per share data) Twelve Months Ended December Three Months Ended December 31, 31, 2023 2022 2023 2022 Revenue $ 646,885 $ 552,995 $ 2,499,766 $ 2,084,279 O

  12. Slide 12: Condensed Consolidated Balance Sheets

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Balance Sheets (Amounts in thousands) December 31, December 31, 2023 2022 Assets Cash and cash equivalents $ 605,378 $ 242,493 Marketable securities 172,266 389,564 Accounts receivable, net 203,623 158,043 Inv

  13. Slide 13: Reconciliation of Core Revenue

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of Core Revenue (Amounts in thousands) GAAP Three Months Ended December 31, 2023 2022 % Change Screening $ 486,706 $ 403,528 21 % Precision Oncology 160,179 143,430 12 % COVID-19 Testing — 6,037 (100) % Total $ 646,88

  14. Slide 14: Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations (Amounts in thousands) Three Months Ended December Twelve Months Ended 31, December 31, 2023 2022 2023 2022 Revenue $ 646,885 $ 552,995 $ 2,499,766 $ 2,084,279 Cost of

  15. Slide 15: EBITDA and Adjusted EBITDA Reconciliations

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information EBITDA and Adjusted EBITDA Reconciliations (Amounts in thousands) Three Months Ended December Twelve Months Ended 31, December 31, 2023 2022 2023 2022 Net loss $ (49,766) $ (127,745) $ (204,149) $ (623,506) Interest expense (1) 7,86

  16. Slide 16: Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow (Amounts in thousands) Three Months Ended December 31, Twelve Months Ended December 31, 2023 2022 2023 2022 Net cash provided by (used in) operatin

Exact Sciences — Q4 2023 Earnings Presentation on 6ix